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Summary The clinicopathological characteristics of breast cancer in 95 women between the ages of 24 and 45 years with a family history of
breast cancer were compared with tumours from 329 women with sporadic disease matched for age and year of diagnosis. There was a trend
for the family history patients to have slightly smaller tumours (mean size 2.49 cm) than the controls (mean 3.04 cm) (Mann-Whitney test,
P= 0.09). A significantly greater proportion of the familial cases had grade IlIl infiltrating ductal carcinoma than did the controls (40% vs 27%;
2= 5.64, P = 0.02). Despite this, there were more cases of operable node-negative disease among the study group than among the controls
(48% vs 32%; X2 = 8.2, P = 0.004). There was a highly significant survival advantage for patients with a family history (X2 = 22.4, P < 0.001).
Five- and 10-year survival rates were 92% and 87% forthose with afamily history compared with 70% and 54% forthose in the control group.
This survival advantage was maintained when patients with operable disease only were considered. In multivariate analysis, which included
age, tumour size, stage, histological grade and family history, family history was an independent predictor of favourable prognosis and, in a
Cox model, was associated with a relative risk of survival of 6.11 (95% Cl 2.81-13.28). These results suggest that familial breast cancer has
a more favourable clinical course than the more common sporadic forms of the disease.
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The prognostic significance ofbreast cancer morphology has been
reviewed extensively. In contrast, there are few studies that have
examined the association between breast cancer histopathology
and a family history of breast cancer (Rosen et al, 1982; Claus et
al, 1993; Fukutomi et al, 1993). There are, however, several anec-
dotal reports of improved survival rates in patients with a family
history of breast cancer (Lynch et al, 1981; Albano et al, 1982).
The few studies carried out since the identification of the BRCAJ
gene have reported a more favourable prognosis for patients from
BRCAI-linked breast/ovarian cancer families (Malone et al, 1996;
Marcus et al, 1996; Rubin et al, 1996).
We have examined the histological characteristics of breast
cancer in women with and without a positive family history to
determine whether familial breast cancers had features similar to
or distinct from sporadic forms. The issue of an improved clinical
outcome has also been explored in this study to determine whether
or not a family history confers a survival advantage to women with
breast cancer.
METHODS
A review of all women with breast cancer diagnosed below the age
of45 years at the ICRF Clinical Oncology Unit orreferred to the SE
Thames Regional Genetics Centre at Guy's Hospital between June
1965 and December 1995 was undertaken. Detailed pedigree data
were obtained to determine the extent ofa hereditary predisposition
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in these women. A total of 95 breast cancer families were ascer-
tained through a proband diagnosed with breast cancer at or below
45 years. Six probands had two or more first-degree and second-
degree affected relatives, 37 had one first- and one second-degree
affected relatives, 27 had only one first-degree affected relative,
while 25 had only second-degree affected relatives. Of the entire
studycohort, nine patients were frombreast/ovarian cancerfamilies.
The clinical and pathological characteristics ofthese 95 patients
diagnosed between the ages of 21 and 45 years and 329 age-
matched controls, i.e. women diagnosed with breast cancer but
with no family history of breast cancer on specific enquiry, were
examined. The controls were matched with the 95 cases for age
and year of diagnosis. Attempts were made to find four matched
controls for each case, but in 37 probands this was not possible. In
ten of these cases, the women were below the age of 30, and 22
were diagnosed in the past 5 years. For 26 cases, it was possible to
obtain only three controls; for seven cases, two matched controls
and for four cases only one matched control were possible. The
cases and controls were examined for the distribution of back-
ground risk factors, clinical and pathological features and relapse-
free and overall survival in all 424 patients (95 cases, 329
controls). We also examined overall and relapse-free survival in
two subgroups: 309 women with invasive operable breast cancer
with known node status (77 cases, 232 controls) and a subset of
196 of these women with invasive operable disease who were
diagnosed and treated in the Imperial Cancer Research Fund
Clinical Oncology Unit at Guy's Hospital, London (55 cases, 141
controls).
The patients have been followed up for a median of 8.6 years
(range 1 month-30 years). Pathological details of the breast
cancers were taken from the histopathology results. The tumours
from the 196 patients diagnosed at Guy's Hospital were typed
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Table 1 Characteristics of cases at time of diagnosis
Risk factors Familial group Control group Significance
(n = 95) (n = 329)
Age at diagnosis (years)
Median (range) 36.0 (24-45) 37.0 (23-45) NS
Age at birth of first child (years)
Median (range) 24.0 (17-37) 25.0 (16-38) NS
Clinical tumour size (cm)
Median (range) 2.0 (0-13) 2.5 (0-15) ap= 0.09
Bilateral disease (n)b
Synchronous 1 (1) 3 (1) NS
Metachronous 10 (11) 34 (10)
Menstrual status (n)b
Premenopausal 94 (99) 326 (99)
Perimenopausal 1 (1) 2 (1) NS
Unknown 1
Parity (n)b
Nulliparous 28 (30) 66 (21)
Parous 66 (70) 256 (80) NS
Unknown 1 7
aMann-Whitney test. bNumbers in parentheses are percentages.
Table 2 Pathological features at presentation
Pathological features Familial Control Significance
group group
(n = 95) (n= 329)
n(%) n(%)
Pathological stage
Operable, node negative 45 (48) 104 (32)
Operable
One to three nodes positive 26 (28) 90 (27)
Four or more nodes positive 9 (10) 51 (16) X2 = 8.2
Positive (number unspecified) 1 (1) P = 0.004
Operable, node unknown 8 (9) 57 (18)
Locally advanced inoperable 4 (4) 24 (7)
Unknown 2 3
Histology
DCIS 6 (7) 13 (4)
Invasive ductal grade 4 (4) 10 (3)
Invasive ductal grade 11 16 (17) 68 (23)
Invasive ductal grade III 37 (40) 80 (27) X2 = 5.64
Invasive lobular 7 (8) 14 (5)
Other invasive lobular 22 (24) 116 (38) P= 0.02a
Unknown 3 28
alnfiltrating ductal carcinomas only.
according to WHO criteria (1980), and histological grade was
determined according to the criteria of Bloom and Richardson (as
modified by Elston) (Elston, 1984).
Statistical methods
The chi-squared test was used for comparison of categorical vari-
ables. Survival curves were produced using the method of Kaplan
and Meier (Kaplan and Meier, 1985). Differences between
survival curves were determined using the log-rank test (Peto et al,
1975). Multivariate analysis was performed using the Cox propor-
tional hazards model (Cox, 1972).
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Figure 1 Overall survival - cases vs controls
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Figure 2 Relapse-free survival - cases vs controls
RESULTS
Comparison of presentation characteristics
Table 1 shows a comparison of the presentation characteristics of
the 95 patients in the family history group and the 329 patients in
the control group. No statistically significant differences were
noted between the two groups, although there was a trend for
patients with a family history to have clinically smaller tumours
(mean size 2.49 cm) than the controls (mean 3.04cm)
(Mann-Whitney test, P = 0.09).
Pathological features
The pathological features at presentation are shown in Table 2. A
greater proportion of the familial cases had operable node-nega-
tive disease, 48% vs 32% (XI = 8.2, P = 0.004). Comparing the 309
women with invasive operable disease in whom nodal status was
known, the number of node-negative cases was still significantly
greater in the study group (55% vs 40%, XI = 4.3, P = 0.04). Ofthe
patients with infiltrating ductal carcinoma, there were significantly
more grade III tumours in the familial group (40% vs 27%,
%2 = 5.64, P = 0.02).
Survival
Univariate analysis
The median follow-up times for the study and control groups were
7.8 (range 8.6 months-30 years) and 8.6 years (range 1 month-
29 years) respectively. The study group had a significantly better
prognosis than the control cases. Figure 1 shows the difference in
overall survival between the two groups (x2, = 22.4, P < 0.001). A
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Figure 3 Overall survival - patients with invasive operable disease
diagnosed at Guy's Breast Unit
Table 3 Summary of results of multivariate analysis of survival
Univariate Multivariate
Variable RRa 95% Clb P-value RR 95% CI P-value
Age 1.07 1.03-1.12 0.002 1.07 1.03-1.12 0.003
Clinical tumour size 1.25 1.18-1.34 <0.0001 1.22 1.12-1.32 <0.0001
Stagec 1.69 1.37-2.08 <0.0001 1.29 1.03-1.63 0.03
Histologyd 2.01 1.37-2.96 0.0004 2.12 1.44-3.12 0.0002
Family historye 5.38 2.49-11.62<0.0001 6.11 2.81-13.28 <0.0001
aRelative risk. b95% Confidence intervals. cStage 1 vs stage 2 vs stage 3,
with stage 5 recorded as stage 2. dGrade vs grade 2 vs grade 3, all other
histologies recorded as grade 2. eNo family history vs any family history. Age
and clinical tumour size were continuous variables.
Table 4 Comparison of survival rates of familial and control cases
Survival rate
5 Year 10 Year Significance
% 95% Cl % 95% Cl
Overall
Familial group 92 83-96 87 76-93 X2 = 22.44
Control group 70 64-75 54 46-60 P<0.001
Relapse free
Familial group 74 63-82 64 51-74 x2 = 14.72
Control group 50 44-56 39 32-45 P < 0.001
difference between the two groups is also seen when considering
relapse-free survival (Figure 2), although the magnitude of the
difference is not so great (X2I = 14.72, P <0.001).
The same effect on survival was seen in the two subgroups of
women with invasive operable disease and known nodal status;
log-rank analysis showed that a family history of breast cancer
conferred a survival advantage in all 309 women with this stage of
the disease (X2 = 19.7, P <0.001) and in the 196 women
diagnosed and treated at Guy's Hospital (X, = 13.05, P < 0.001)
(Figure 3).
Multivariate analysis
In an attempt to demonstrate whether or not a family history of
breast cancer was an independent predictor of good prognosis, a
multivariate analysis was performed. The factors included in the
multivariate model were age, clinical tumour size, stage, histolog-
ical grade and family history of breast cancer. The results of the
multivariate analysis are summarized in Table 3. A family history
of breast cancer was found to be an independent indicator of a
favourable prognosis with a relative risk of 6.11 (95% CI
2.81-13.28). This analysis was repeated for all 309 patients with
invasive operable disease with known nodal status and for the 196
of these women diagnosed at Guy's Hospital, with nodal status
replacing stage as a variable in the model. The pattern of the
results was the same in all groups, despite the fact that some ofthe
women were diagnosed and managed elsewhere before coming to
the Guy's Hospital Breast Unit. A family history of breast cancer
remained the strongest predictor of outcome; the women with
known nodal status had a relative risk of 4.73 (95% CI
2.03-11.00); for the women diagnosed at Guy's Hospital, the
relative risk was 6.54 (95% CI 2.01-21.28). Similar results were
obtained when relapse-free survival was considered, rather than
overall survival.
DISCUSSION
The results from this study suggest that patients with a family
history of breast cancer have a survival advantage over those
without a family history. The 5- and 10-year overall survival rates
in the family history group were 92% and 87% respectively,
compared with rates of 70% and 54% in the control group.
Similarly, for relapse-free survival, the rates were 74% and 64%
for the family history group compared with 50% and 39% for the
control group (Table 4). The better outcome could not be attributed
to difference in age at diagnosis or the histopathological profile of
the tumours in the two groups. Despite the familial cases having a
higher grade of tumour at the time of diagnosis, they were less
likely to have nodal involvement. It is unclear whether the signifi-
cance of an earlier stage of presentation in the familial group is a
reflection ofa real biological difference or a greater awareness and
increased surveillance in women with a family history.
These results reflect those offour other recent studies looking at
survival rates in women from high-risk breast cancer families. The
study by Porter et al (1994) found an 83% 5-year survival rate in
35 women from eight families with prior evidence of linkage to
BRCA] compared with a 61% survival in 910 age-matched
controls. A study by Marcus et al (1996) of 175 breast carcinomas
in women from 52 families (26 of which were linked to BRCAI)
and 187 breast carcinomas from women without a family history
similarly found a non-significant trend towards better survival
with fewer recurrences in the family history group as a whole,
without adjustment for age and stage at diagnosis. Within the
family history group, the BRCAI-related patients had fewer recur-
rences than other hereditary breast cancer patients (P = 0.013).
This was despite the fact that the BRCAl-related tumours,
although having a lower DNA index, showed greater proliferative
activity in terms of mitotic grade and S-phase fraction. Similarly,
Malone et al (1996), in an analysis of733 cases, found that the risk
of dying among affected women who had a first-degree family
history of breast cancer was half that of women with no family
history. Additionally, the difference in survival rates could not be
attributed to differences in screening or treatment between the two
groups. A major strength of the latter study was that it had a
population-based design, which therefore minimized a selection
bias for women with varying family histories. The multicentre
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study of Rubin et al (1996) of 53 patients with ovarian cancer and
germline BRCAJ mutations in patients with advanced-stage
disease similarly reports a significantly more favourable outcome
for the familial cases in comparison to sporadic ovarian cancers.
The actuarial median survival for 43 of their patients with a
defined BRCAJ mutation was 77 months compared with 29
months for matched controls (P < 0.001).
There are clearly inherent limitations in the current study, as with
other retrospective studies reported in the literature. A fact high-
lighted in a recent correspondence in the New England Journal of
Medicine (Canistra et al, 1997), afterthepublication ofthe paperby
Rubin et al (1996). We have tried to overcome many of the prob-
lems raised by the selection of our control group, which was
matched for stage ofdisease and yearofdiagnosis. Although not all
patients were treated in our unit for the duration oftheirdisease, the
outcome for the different groups was similar. Despite the best
efforts to avoid selection bias, the only way to overcome them is by
a large prospective study that compares the outcome of known
BRCAJIBRCA2 carriers with non-mutation carriers. Our results
need to be interpreted in the light of a relatively short median
follow-up time of 8.6 years. Some of the younger patients (below
30 years) were diagnosed recently and, consequently, have made a
lesser contribution to the overall survival analysis. It will therefore
be important to reanalyse the data in 5 years, when a longer follow-
up time will have elapsed for the patients in this study. It is not
known whether the presence of a family history contributed to
earlier diagnosis of breast cancer in the study group. Such knowl-
edge might lead to increased vigilance, resulting in more biopsies
for benign disease and more frequent mammograms.
Unfortunately, such data were not available for many patients.
Nevertheless, a clear effect on survival rates was seen in the study
group even after adjusting for differences in features, such as
tumour size, stage and nodal involvement, between the two groups.
Some recent reports (Bignon et al, 1995; Jacquemier et al, 1995;
Marcus et al, 1996) have highlighted an association between grade
III ductal carcinomas and female BRCAJ gene carriers. Loss of
heterozygosity (LOH) analyses have shown consistent loss of the
wild-type allele on 17q in breast tumours from families linked to
BRCA]. Interestingly, a high rate of LOH at the BRCA2 locus has
also been shown in one family with a pathogenic BRCAJ mutation
that had priorevidence of 17q LOH (Kelsell et al, 1996). An analysis
of 118 unselected cases ofprimary breast tumours showed an excess
of carcinomas concordant for loss or retention at both BRCAJ and
BRCA2 loci in grade III tumours but not in grade I or II ductal carci-
nomas. These observations suggest a combined role forBRCA] and
BRCA2 in the tumorigenic pathway, particularly in grade III tumours
(Kelsell et al, 1996). Patients with combined loss at both loci also
appeared to have a better survival rate than those with loss at only
one locus (D Barnes, personal communication, 1996).
At present, it is not known what proportion of breast cancer
cases in our study group may be attributable to an underlying
mutation in the BRCAI or BRCA2 genes, although this is currently
being ascertained. A preliminary search for constitutional BRCAJ
mutations in 55 of these families has found such mutations to be
implicated not only in the larger families but also in some smaller
kindreds. To date, six definite pathogenic BRCAI mutations have
been defined in the study group. Two ofthe mutations were found
in nine sporadic cases screened so far (Greenman et al, 1998).
Furthermore, there may be some unrecognized mutation carriers
among our control group of patients. If this was so, and their
outcome was similar to that ofthe familial patients, the difference
between our two groups would be even larger.
These preliminary data from 95 patients with familial breast
cancer and 329 age-matched controls suggest that a family history
is significantly related to improved prognosis in women with
breast cancer. The familial cases had higher grade tumours at
presentation but, despite this, had less nodal involvement and
significantly better overall and relapse-free survival rates. The
precise mechanism that could account for a better prognosis in the
familial cases is unclear. It is important that it is investigated in
future studies with a longer follow-up. These will need to address
whether or not these observed differences in survival rates reveal a
true pathobiological difference in tumour behaviour and, if so,
how these relate to underlying BRCA]/2 mutations. If particular
mutations are associated with a less aggressive nature of some
tumours or a better response to chemotherapy, it is conceivable
that this may account for the improved survival rates observed.
Clarification of this and the role of other breast cancer suscepti-
bility genes in the tumorigenic pathway is likely to have an impor-
tant bearing on the counselling of women from such high-risk
breast cancer families.
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